Pharmaxis (Pharmaxis) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 06, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharmaxis's float shares is 0.00 Mil. Pharmaxis's total shares outstanding is 30.15 Mil. Pharmaxis's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharmaxis's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharmaxis's Institutional Ownership is 0.04%.

Pharmaxis Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Pharmaxis's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	30.15
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaxis (Pharmaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines

From GuruFocus

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis

By Business Wire Business Wire • 11-02-2020

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

By PRNewswire PRNewswire • 08-05-2021

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

By PRNewswire PRNewswire • 08-31-2021

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

By PRNewswire PRNewswire • 11-09-2021

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

By PRNewswire PRNewswire • 10-05-2021

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

By PRNewswire PRNewswire • 08-04-2021